A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03843359

Enrollment

Registered

2019-02-18

Start date

2019-03-12

Completion date

2026-01-09

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

GSK3745417, Dostarlimab, Anti-Programmed death receptor-1 (PD-1), Monoclonal antibody, Solid tumor, First time in human, Stimulator of Interferon Genes, STING

Brief summary

This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.

Interventions

DRUGGSK3745417

GSK3745417 will be administered.

DRUGDostarlimab

Dostarlimab will be administered.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Masking description

This will be an Open-label study.

Intervention model description

In Part 1A, escalating doses of GSK3745417 will be evaluated and in Part 2A, escalating doses of GSK3745417 in combination with dostarlimab will be evaluated as guided by the Bayesian Logistic Regression Model (BLRM).

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participant must be more than or equal to (\>=)18 years of age. * Participants with advanced/recurrent solid tumors, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established. * Histological or cytological documentation of an advanced solid tumor. * Participants must provide a fresh biopsy. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. * Adequate organ function per protocol specifications. * Male or female participants. * Female participants are eligible to participate if they are not breastfeeding or pregnant (or intend to breastfeed or become pregnant). Women of childbearing potential must use a highly effective method of contraception. * Capable of giving signed informed consent.

Exclusion criteria

* Active autoimmune disease that has required systemic disease modifying or immunosuppressive treatment within the last 2 years. * Concurrent medical condition requiring the use of systemic immunosuppressive treatment within 28 days before the first dose of study treatment. * Current unstable liver or biliary disease. * History of vasculitis at any time prior to study treatment. * Evidence or history of significant active bleeding or coagulation disorder. * Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen or hepatitis C. * QT duration corrected for heart rate by Fridericia's formula (QTcF) more than (\>)450 milliseconds (msec) or QTcF \>480 msec for participants with bundle branch block. * Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction. * Recent history of allergen desensitization therapy within 4 weeks of starting study treatment. * History or evidence of cardiovascular (CV) risk * Recent (within the past 6 months) history of symptomatic pericarditis. * History of idiopathic pulmonary fibrosis, interstitial lung disease, or organizing pneumonia, or evidence of active, non-infectious pneumonitis. * History of (non-infectious) pneumonitis that required steroids or current pneumonitis. * Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions. * Prior treatment with the following agents: 1. Stimulator of Interferon Genes (STING) agonist at any time. 2. Anticancer therapy or investigational therapy or used an investigational device within 28 days or 5 half-lives of the drug, whichever is shorter. 3. Checkpoint inhibitors, including Programmed death receptor-1 (PD-1), Programmed death Ligand-1 (PD-L1), PD-L2 and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors within 28 days. 4. Prior radiation therapy: permissible if at least 1 non-irradiated measurable lesion is available for assessment according to RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. * Pregnant and/or breast feeding participants or those who plan to become pregnant and/or breastfeed. * Receipt of any live vaccine within 30 days of the start of study treatment. * Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation. * Major surgery less than or equal to (\<=)28 days before the first dose of study treatment. Participants must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment. * Participants with signs/symptoms suggestive of Coronavirus Disease-2019 (COVID-19) within 14 days of study entry, or with known exposure to COVID-19 within 14 days prior to study entry. * Participants are excluded from Part 2A of the study if they have known hypersensitivity to dostarlimab or associated excipients.

Design outcomes

Primary

Measure	Time frame	Description
Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)	Up to 21 Days	AE is DLT if deemed clinically relevant,attributed to study intervention \& met DLT criteria:CytokineReleaseSyndrome (CRS) (Grade(G) 3/4);Liver Toxicity: ALT≥3xULN + bilirubin≥2xULN/INR\>1.5, ALT≥5x ULN+≥2x baseline with liver,metastases/tumor infiltration or HCC;G≥3 non-hematologic exceptions: Transient lab abnormalities, CRS≤G2,Controlled diarrhea,Resolving nausea/vomiting,Alopecia,G3 fatigue\<7 days,G3 headache resolving in 24 hrs;G≥3 immune-related toxicity unresolved in 8 days despite therapy and G≥3 infusion reactions included;Other toxicities: G≥2 uveitis, Unresolved eye pain/blurred vision in 2 wks,Endocrine toxicity needing hormone replacement,Colitis/diarrhea unresolved for ≥7Days despite steroids,ICANS;Hematologic toxicity includes: Neutropenia(G4 ≥7Days or G3/4 with infection/febrile neutropenia),Thrombocytopenia (G4/G3 with bleeding/transfusion),Anemia (G4/G3 needing transfusion);Other events deemed DLTs by the investigator and GSK Medical Monitor per NCI-CTCAE v5.0
Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)	Up to 29 Days	AE is DLT if deemed clinically relevant,attributed to study intervention \& met DLT criteria:CytokineReleaseSyndrome (CRS) (Grade(G) 3/4);Liver Toxicity: ALT≥3xULN + bilirubin≥2xULN/INR\>1.5, ALT≥5x ULN+≥2x baseline with liver,metastases/tumor infiltration or HCC;G≥3 non-hematologic exceptions: Transient lab abnormalities, CRS≤G2,Controlled diarrhea,Resolving nausea/vomiting,Alopecia,G3 fatigue\<7 days,G3 headache resolving in 24 hrs;G≥3 immune-related toxicity unresolved in 8 days despite therapy and G≥3 infusion reactions included;Other toxicities: G≥2 uveitis, Unresolved eye pain/blurred vision in 2 wks,Endocrine toxicity needing hormone replacement,Colitis/diarrhea unresolved for ≥7Days despite steroids,ICANS;Hematologic toxicity includes: Neutropenia(G4 ≥7Days or G3/4 with infection/febrile neutropenia),Thrombocytopenia (G4/G3 with bleeding/transfusion),Anemia (G4/G3 needing transfusion);Other events deemed DLTs by the investigator and GSK Medical Monitor per NCI-CTCAE v5.0
Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Up to 29 Days	AE is DLT if deemed clinically relevant,attributed to study intervention \& met DLT criteria:CytokineReleaseSyndrome (CRS) (Grade(G) 3/4);Liver Toxicity: ALT≥3xULN + bilirubin≥2xULN/INR\>1.5, ALT≥5x ULN+≥2x baseline with liver,metastases/tumor infiltration or HCC;G≥3 non-hematologic exceptions: Transient lab abnormalities, CRS≤G2,Controlled diarrhea,Resolving nausea/vomiting,Alopecia,G3 fatigue\<7 days,G3 headache resolving in 24 hrs;G≥3 immune-related toxicity unresolved in 8 days despite therapy and G≥3 infusion reactions included;Other toxicities: G≥2 uveitis, Unresolved eye pain/blurred vision in 2 wks,Endocrine toxicity needing hormone replacement,Colitis/diarrhea unresolved for ≥7Days despite steroids,ICANS;Hematologic toxicity includes: Neutropenia(G4 ≥7Days or G3/4 with infection/febrile neutropenia),Thrombocytopenia (G4/G3 with bleeding/transfusion),Anemia (G4/G3 needing transfusion);Other events deemed DLTs by the investigator and GSK Medical Monitor per NCI-CTCAE v5.0
Parts 2A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Up to 29 Days	AE is DLT if deemed clinically relevant,attributed to study intervention \& met DLT criteria:CytokineReleaseSyndrome (CRS) (Grade(G) 3/4);Liver Toxicity: ALT≥3xULN + bilirubin≥2xULN/INR\>1.5, ALT≥5x ULN+≥2x baseline with liver,metastases/tumor infiltration or HCC;G≥3 non-hematologic exceptions: Transient lab abnormalities, CRS≤G2,Controlled diarrhea,Resolving nausea/vomiting,Alopecia,G3 fatigue\<7 days,G3 headache resolving in 24 hrs;G≥3 immune-related toxicity unresolved in 8 days despite therapy and G≥3 infusion reactions included;Other toxicities: G≥2 uveitis, Unresolved eye pain/blurred vision in 2 wks,Endocrine toxicity needing hormone replacement,Colitis/diarrhea unresolved for ≥7Days despite steroids,ICANS;Hematologic toxicity includes: Neutropenia(G4 ≥7Days or G3/4 with infection/febrile neutropenia),Thrombocytopenia (G4/G3 with bleeding/transfusion),Anemia (G4/G3 needing transfusion);Other events deemed DLTs by the investigator and GSK Medical Monitor per NCI-CTCAE v5.0
Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	Up to approximately 62 weeks	AE is any untoward medical occurrence in clinical investigation participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. AEs were graded by the investigator according to National Cancer Institute Common Terminology Criteria for AE (NCI-CTCAE) (version 5.0):G1=Mild,G2=Moderate,G3=Severe or medically significant but not immediately life-threatening,G4=Life-threatening consequences,G5=Death related AE.
Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	Up to approximately 93 weeks	AE is any untoward medical occurrence in clinical investigation participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. AEs were graded by the investigator according to NCI-CTCAE v5.0: G1=Mild, G2=Moderate, G3=Severe or medically significant but not immediately life-threatening, G4=Life-threatening consequences, G5=Death related AE.
Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	Up to 30.3 weeks	AE is any untoward medical occurrence in clinical investigation participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. AEs were graded by the investigator according to NCI-CTCAE v5.0: G1=Mild, G2=Moderate, G3=Severe or medically significant but not immediately life-threatening, G4=Life-threatening consequences, G5=Death related AE.

Secondary

Measure	Time frame	Description
Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	Pre-dose on weeks(W) 1-6,9,10,12,19,55;end of infusion(EOI)+5minute(min) on W 1-6, 9,10,12,19,55;EOI+4 hour(HR)/8 HR on W 1-6, 9, 10, 12, 19;EOI+15min/30min/45min/1HR on W 1-6, 9,12;EOI+24HR on W 1-6, 9,10,12; EOI+2HR on W 1-6,9,10,12,19,55	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	Week 1 to 6, 9, 10, 12, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	Week 1 to 6, 9, 10, 12, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	Week 1 to 6, 9, 10, 12, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	Pre-dose on W 1, 4, 7, 10, 13, 16, 19; EOI+5min/ 15min/ 30 min/ 45 min/1HR/ 2HR/ 4HR on W 1, 4, 7, 10, 13, 16, 19; EOI+8HR/ 24HR on W 1, 4, 7, 10, 13, 16	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	Week 1, 4, 7, 10, 13, 16, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	Week 1, 4, 7, 10, 13, 16, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	Week 1, 4, 7, 10, 13, 16, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.
Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Pre-dose,EOI+5min/2HR/4HR on W 1 to 5, 7, 10, 13, 19, 37, 55; EOI+15min/ 30min/ 45 min/ 1HR on W 1, 4, 7; EOI+8HR on W 1 to 5, 7, 10, 13, 19; EOI+24HR on W 1 to 5, 7, 10	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Week 1 to 5, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Week 1 to 5, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Week 1 to 5, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	Pre-dose and EOI+5min/ 2HR/ 4HR on W 1, 2, 5, 6, 8, 11, 14, 20, 38; EOI+15min/ 30min/ 45min/ 1HR/ 6HR on W 1 and 8; EOI+8HR in W 1, 2, 5, 6, 8; EOI+24HR on W 1, 2, 5, 8.	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	Week 1, 2, 5, 6, 8	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	Week 1, 2, 5, 6, 8	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	Week 1, 2, 5, 6, 8	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Pre-dose on W 1, 4, 7, 10, 13, 19, 37, 55, 73, 91; EOI+5min/ 4HR on W 1, 4, 7, 10, 13, 19, 37, 55, 91; EOI+15min/ 30min/ 45min/ 1HR/ 6HR on W 1, 4, 7; EOI+2HR on W 1, 4, 7, 10, 13, 19, 37, 55, 73; EOI+8HR/24 HR on W 1, 4, 7, 10, 13, 19, 91	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Week 1, 4, 7, 10, 13, 19, 91	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Week 1, 4, 7, 10, 13, 19, 91	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Week 1, 4, 7, 10, 13, 19, 91	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Pre-dose and EOI+5min/2HR/ 4HR/ 8HR on crossover W 1, 4, 7, 10, 13, 19; EOI+12HR/18HR on crossover W 4; EOI+15min/ 30 min/45 min/1HR/6HR/24HR on crossover W 1, 4, 7	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Crossover Week 1, 4, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Crossover Week 1, 4, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	Crossover Week 1, 4, 7, 10, 13, 19	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Pre-dose and EOI+5min/ 2HR/4HR on crossover W 1-4, 7,10,19; EOI+15min/30 min/45 min/1HR/ 6HR/ 24HR on crossover W 1,4,7;EOI+12HR/18HR on crossover W 4;EOI+8HR on crossover W 1-4,7,10	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Crossover Week 1, 2, 3, 4, 5, 7, 10	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Crossover Week 1, 2, 3, 4, 5, 7, 10	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.
Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	Crossover Week 1, 2, 3, 4, 5, 7, 10	Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Countries

Australia, Canada, France, Japan, Netherlands, South Korea, Spain, United States

Contacts

STUDY_DIRECTORGSK Clinical Trials

GlaxoSmithKline

Participant flow

Recruitment details

This study consisted of 2 phases - Dose Escalation (Part 1A and Part 2A) and Dose Expansion (Part 1B and Part 2B). As pre-specified in protocol, dose expansion phases were not conducted following sponsor's decision to cease further enrolment into the study.

Pre-assignment details

The results presented are based on the data cut-off date of 05 Apr 2024. Those participants still benefiting from study drug in the opinion of their treating physician continued to receive study drug in Post Analysis Continued Treatment (PACT) phase and their data will be reported after they stop receiving treatment as per protocol.

Participants by arm

Arm	Count
Part 1A: GSK3745417 0.1 mg (Q3W) Participants with advanced solid tumors received a 0.1 mg dose of GSK3745417 as an intravenous (IV) infusion every three weeks (Q3W) until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	3
Part 1A: GSK3745417 0.2 mg (Q3W) Participants with advanced solid tumors received a 0.2 mg dose of GSK3745417 as an IV infusion Q3W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	6
Part 1A: GSK3745417 0.1 mg (Q1W) Participants with Advanced Solid Tumors received 0.1 mg GSK3745417 as an IV infusion once a week (Q1W) until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	14
Part 1A: Japan GSK3745417 0.1 mg (Q1W) Japanese participants with Advanced Solid Tumors received 0.1 mg GSK3745417 as an IV infusion Q1W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	2
Part 1A: GSK3745417 0.2 mg (Q1W) Participants with Advanced Solid Tumors received 0.2 mg GSK3745417 as an IV infusion Q1W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	19
Part 1A: GSK3745417 0.4 mg (Q1W) Participants with Advanced Solid Tumors received 0.4 mg GSK3745417 as an IV infusion Q1W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	10
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis Participants with Advanced Solid Tumors and effect of prophylaxis received 0.4 mg GSK3745417 as an IV infusion Q1W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	9
Part 2A: GSK3745417 0.1 mg (Q3W) + Dostarlimab Participants with Advanced Solid Tumors received 0.1 mg GSK3745417 as an IV infusion Q3W in combination with Dostarlimab 500 mg IV Q3W till Day 85 (Week 13), followed by 1000 mg IV every 6 weeks (Q6W) for subsequent doses until Day 722 or until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	4
Part 2A: GSK3745417 0.2 mg (Q3W) + Dostarlimab Participants with Advanced Solid Tumors received 0.2 mg GSK3745417 as an IV infusion Q3W in combination with Dostarlimab 500 mg IV Q3W till Day 85 (Week 13), followed by 1000 mg IV Q6W for subsequent doses until Day 722 or until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	12
Part 2A: GSK3745417 0.1 mg (Q1W) + Dostarlimab Participants with Advanced Solid Tumors received 0.1 mg GSK3745417 as an IV infusion Q1W in combination with Dostarlimab 500 mg IV Q3W till Day 85 (Week 13), followed by 1000 mg IV Q6W for subsequent doses until Day 722 or until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	4
Part 2A: Imaging GSK3745417 0.1 mg (Q1W) + Dostarlimab Participants with Advanced Solid Tumors received 0.1 mg GSK3745417 as an IV infusion Q1W in combination with Dostarlimab 500 mg IV Q3W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier. Additionally, for participants in this arm T-cell activation through Positron Emission Tomography (PET) imaging of 18F-labeled analog of arabinofuranosyl guanine (\[18F\]F-AraG) and the biodistribution of radiolabeled GSK3745417 were performed.	3
Part 2A: GSK3745417 0.2 mg (Q1W) + Dostarlimab Participants with Advanced Solid Tumors received 0.2 mg GSK3745417 as an IV infusion Q1W combination with Dostarlimab 500 mg IV Q3W till Day 85 (Week 13), followed by 1000 mg IV Q6W for subsequent doses until Day 722 or until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier.	10
Part 2A: Imaging GSK3745417 0.2 mg (Q1W) + Dostarlimab Participants with Advanced Solid Tumors received 0.2 mg GSK3745417 as an IV infusion Q1W in combination with Dostarlimab 500 mg IV Q3W until disease progression, death, the onset of unacceptable toxicity (including meeting liver chemistry stopping criteria), withdrawal of consent, or upto 2 years, whichever occurred earlier. Additionally, for participants in this arm T-cell activation through PET imaging of \[18F\]F-AraG and the biodistribution of radiolabeled GSK3745417 were performed.	1
Total	97

Baseline characteristics

Characteristic	Part 1A: GSK3745417 0.1 mg (Q3W)	Part 1A: GSK3745417 0.2 mg (Q3W)	Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Part 2A: GSK3745417 0.1 mg (Q3W) + Dostarlimab	Part 2A: GSK3745417 0.2 mg (Q3W) + Dostarlimab	Part 2A: GSK3745417 0.1 mg (Q1W) + Dostarlimab	Part 2A: Imaging GSK3745417 0.1 mg (Q1W) + Dostarlimab	Part 2A: GSK3745417 0.2 mg (Q1W) + Dostarlimab	Part 2A: Imaging GSK3745417 0.2 mg (Q1W) + Dostarlimab	Total
Age, Continuous	50.0 YEARS STANDARD_DEVIATION 1.73	46.8 YEARS STANDARD_DEVIATION 17.81	55.8 YEARS STANDARD_DEVIATION 11.44	66.0 YEARS STANDARD_DEVIATION 2.83	56.5 YEARS STANDARD_DEVIATION 15.13	53.3 YEARS STANDARD_DEVIATION 11.41	51.3 YEARS STANDARD_DEVIATION 9.08	66.3 YEARS STANDARD_DEVIATION 5.8	55.5 YEARS STANDARD_DEVIATION 12.21	54.5 YEARS STANDARD_DEVIATION 7.14	61.7 YEARS STANDARD_DEVIATION 12.5	58.0 YEARS STANDARD_DEVIATION 10.45	NA YEARS	55.5 YEARS STANDARD_DEVIATION 12.11
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	3 Participants	6 Participants	14 Participants	2 Participants	19 Participants	10 Participants	9 Participants	4 Participants	12 Participants	4 Participants	3 Participants	10 Participants	1 Participants	97 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	5 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	3 Participants	0 Participants	1 Participants	7 Participants
Race (NIH/OMB) White	3 Participants	6 Participants	13 Participants	0 Participants	19 Participants	10 Participants	9 Participants	3 Participants	10 Participants	3 Participants	0 Participants	8 Participants	0 Participants	84 Participants
Sex: Female, Male Female	1 Participants	3 Participants	7 Participants	0 Participants	9 Participants	7 Participants	7 Participants	4 Participants	4 Participants	2 Participants	0 Participants	5 Participants	1 Participants	50 Participants
Sex: Female, Male Male	2 Participants	3 Participants	7 Participants	2 Participants	10 Participants	3 Participants	2 Participants	0 Participants	8 Participants	2 Participants	3 Participants	5 Participants	0 Participants	47 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk	EG013 affected / at risk	EG014 affected / at risk	EG015 affected / at risk
deaths Total, all-cause mortality	3 / 3	5 / 6	6 / 14	0 / 2	14 / 19	7 / 10	8 / 9	3 / 4	8 / 12	4 / 4	2 / 3	8 / 10	0 / 1	0 / 1	1 / 4	2 / 5
other Total, other adverse events	2 / 3	5 / 6	14 / 14	2 / 2	19 / 19	10 / 10	9 / 9	4 / 4	12 / 12	4 / 4	3 / 3	10 / 10	1 / 1	1 / 1	3 / 4	5 / 5
serious Total, serious adverse events	0 / 3	0 / 6	4 / 14	0 / 2	7 / 19	3 / 10	2 / 9	1 / 4	6 / 12	3 / 4	2 / 3	4 / 10	1 / 1	0 / 1	1 / 4	1 / 5

Outcome results

Primary

Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

AE is any untoward medical occurrence in clinical investigation participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. AEs were graded by the investigator according to NCI-CTCAE v5.0: G1=Mild, G2=Moderate, G3=Severe or medically significant but not immediately life-threatening, G4=Life-threatening consequences, G5=Death related AE.

Time frame: Up to 30.3 weeks

Population: All treated population. Each participant was counted only once, based on the highest grade they experienced across all adverse events.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	1 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	1 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	2 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	3 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants

Primary

Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)

AE is DLT if deemed clinically relevant,attributed to study intervention & met DLT criteria:CytokineReleaseSyndrome (CRS) (Grade(G) 3/4);Liver Toxicity: ALT≥3xULN + bilirubin≥2xULN/INR\>1.5, ALT≥5x ULN+≥2x baseline with liver,metastases/tumor infiltration or HCC;G≥3 non-hematologic exceptions: Transient lab abnormalities, CRS≤G2,Controlled diarrhea,Resolving nausea/vomiting,Alopecia,G3 fatigue\<7 days,G3 headache resolving in 24 hrs;G≥3 immune-related toxicity unresolved in 8 days despite therapy and G≥3 infusion reactions included;Other toxicities: G≥2 uveitis, Unresolved eye pain/blurred vision in 2 wks,Endocrine toxicity needing hormone replacement,Colitis/diarrhea unresolved for ≥7Days despite steroids,ICANS;Hematologic toxicity includes: Neutropenia(G4 ≥7Days or G3/4 with infection/febrile neutropenia),Thrombocytopenia (G4/G3 with bleeding/transfusion),Anemia (G4/G3 needing transfusion);Other events deemed DLTs by the investigator and GSK Medical Monitor per NCI-CTCAE v5.0

Time frame: Up to 21 Days

Population: DLT Evaluable population included All Treated population who completed at least 21 days of DLT period or discontinued from treatment within 21 days due to an AE meeting the definition of a DLT.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)	2 Participants

Primary

Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)

Time frame: Up to 29 Days

Population: DLT Evaluable population included All Treated population who completed at least 29 days of DLT period or discontinued from treatment within 29 days due to an AE meeting the definition of a DLT.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)	0 Participants

Primary

Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

AE is any untoward medical occurrence in clinical investigation participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. AEs were graded by the investigator according to National Cancer Institute Common Terminology Criteria for AE (NCI-CTCAE) (version 5.0):G1=Mild,G2=Moderate,G3=Severe or medically significant but not immediately life-threatening,G4=Life-threatening consequences,G5=Death related AE.

Time frame: Up to approximately 62 weeks

Population: All treated population included all participants who received at least one dose of GSK3745417. Each participant was counted only once, based on the highest grade they experienced across all adverse events.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	2 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	4 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	1 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	6 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	6 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	5 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	8 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	5 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	5 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	5 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	5 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	3 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	3 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	2 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	5 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W) Prophylaxis	Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants

Primary

Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Time frame: Up to 29 Days

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	0 Participants

Primary

Parts 2A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Time frame: Up to 29 Days

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	0 Participants

Primary

Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

Time frame: Up to approximately 93 weeks

Population: All treated population. Each participant was counted only once, based on the highest grade they experienced across all adverse events.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	1 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	2 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	1 Participants
Part 1A: GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	2 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	4 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	1 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	2 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	1 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	2 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	3 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	2 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	3 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	4 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	2 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	2 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	5 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.2 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	2 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 1	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 2	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 5	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 1	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 2	1 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	STEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 3	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 4	0 Participants
Part 1A: GSK3745417 0.4 mg (Q1W)	Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity	TEAEs, Grade 5	0 Participants

Secondary

Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 2, 3, 4, 5, 7, 10

Population: Pharmacokinetic (PK) population. The number analyzed for each timepoint reflects the number of participants from the Overall PK population with a non-missing value at the specified time point.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER	47.4854 h*ng/mL	Geometric Coefficient of Variation 61.409
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER	119.0544 h*ng/mL	Geometric Coefficient of Variation 129.1524
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER	152.6791 h*ng/mL	Geometric Coefficient of Variation 93.5753
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER	45.7777 h*ng/mL	Geometric Coefficient of Variation 183.4279
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5 CROSSOVER	41.5618 h*ng/mL	Geometric Coefficient of Variation 39.4549
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER	23.9841 h*ng/mL	Geometric Coefficient of Variation 110.4741
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER	81.4712 h*ng/mL	—

Secondary

Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 4, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	1589.8051 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	914.3149 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	3058.1703 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	302.9813 h*ng/mL	Geometric Coefficient of Variation 53.3033
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	979.6423 h*ng/mL	Geometric Coefficient of Variation 32.74
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER	181.2630 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER	200.4303 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	193.0653 h*ng/mL	Geometric Coefficient of Variation 68.7457
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER	201.3292 h*ng/mL	Geometric Coefficient of Variation 46.6743

Secondary

Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 2, 3, 4, 5, 7, 10

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER	18.932 ng/mL	Geometric Coefficient of Variation 64.77
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER	12.504 ng/mL	Geometric Coefficient of Variation 90.216
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER	13.412 ng/mL	Geometric Coefficient of Variation 34.669
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER	15.899 ng/mL	Geometric Coefficient of Variation 60.615
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5 CROSSOVER	22.354 ng/mL	Geometric Coefficient of Variation 19.308
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER	16.580 ng/mL	Geometric Coefficient of Variation 49.604
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER	34.700 ng/mL	—

Secondary

Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 4, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	25.000 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	10.700 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	28.900 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	46.371 ng/mL	Geometric Coefficient of Variation 38.725
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	39.435 ng/mL	Geometric Coefficient of Variation 24.259
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER	66.300 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER	69.700 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	43.381 ng/mL	Geometric Coefficient of Variation 36.411
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER	47.379 ng/mL	Geometric Coefficient of Variation 17.834

Secondary

Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Pre-dose and EOI+5min/ 2HR/4HR on crossover W 1-4, 7,10,19; EOI+15min/30 min/45 min/1HR/ 6HR/ 24HR on crossover W 1,4,7;EOI+12HR/18HR on crossover W 4;EOI+8HR on crossover W 1-4,7,10

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+5MIN	15.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+15MIN	14.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+30MIN	13.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+45MIN	10.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+1HR	9.530 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+2HR	5.780 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+4HR	2.520 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+6HR	1.130 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+8HR	0.507 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER, EOI+5MIN	20.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER, EOI+2HR	10.040 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER, EOI+4HR	3.845 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER, EOI+8HR	0.968 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER, EOI+5MIN	17.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER, EOI+2HR	9.065 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER, EOI+4HR	5.125 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER, EOI+8HR	0.826 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+5MIN	15.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+15MIN	14.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+30MIN	12.750 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+45MIN	11.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+1HR	10.415 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+2HR	6.315 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+4HR	2.325 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+6HR	0.895 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+8HR	0.384 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+12HR	0.248 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+18HR	0.159 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER, EOI+24HR	0.055 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+5MIN	17.500 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+15MIN	15.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+30MIN	11.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+45MIN	9.550 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+1HR	7.995 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+2HR	4.415 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+4HR	1.503 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+6HR	0.364 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+8HR	0.199 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER, EOI+5MIN	34.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER, EOI+2HR	13.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER, EOI+4HR	6.430 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER, EOI+8HR	1.790 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19 CROSSOVER, EOI+5MIN	37.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19 CROSSOVER, EOI+2HR	19.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19 CROSSOVER, EOI+4HR	12.500 ng/mL

Secondary

Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Pre-dose and EOI+5min/2HR/ 4HR/ 8HR on crossover W 1, 4, 7, 10, 13, 19; EOI+12HR/18HR on crossover W 4; EOI+15min/ 30 min/45 min/1HR/6HR/24HR on crossover W 1, 4, 7

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, PREDOSE	8.340 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, PREDOSE	3.320 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+5MIN	14.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+5MIN	25.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+15MIN	18.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+1HR	14.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+30MIN	20.500 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+15MIN	13.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+45MIN	17.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+15MIN	22.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+2HR	8.290 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+30MIN	16.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+4HR	7.130 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+2HR	10.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+6HR	11.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+45MIN	10.500 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+8HR	4.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+1HR	16.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+24HR	3.210 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+1HR	10.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+4HR	6.320 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+5MIN	10.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+2HR	6.490 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+2HR	3.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+30MIN	18.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+4HR	2.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+4HR	6.330 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+6HR	4.780 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, PREDOSE	3.970 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+6HR	8.820 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+5MIN	22.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+5MIN	28.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+2HR	9.580 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+8HR	4.760 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+4HR	5.140 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+8HR	6.940 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+12HR	4.470 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, PREDOSE	4.110 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+45MIN	17.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+5MIN	10.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+18HR	10.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+2HR	4.570 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+24HR	3.780 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+24HR	2.180 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+5MIN	56.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+2HR	21.750 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+4HR	9.525 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, EOI+8HR	5.730 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+1HR	32.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+5MIN	39.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+15MIN	40.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+30MIN	31.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+45MIN	29.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+1HR	27.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+2HR	19.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+4HR	12.025 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+6HR	8.885 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+8HR	2.835 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER, EOI+24HR	0.327 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+5MIN	49.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+15MIN	45.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+30MIN	38.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+45MIN	38.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+1HR	33.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+2HR	23.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+4HR	12.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+6HR	5.740 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+8HR	4.290 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+12HR	1.560 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+5MIN	48.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+18HR	0.969 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER, EOI+24HR	0.719 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+15MIN	40.750 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+30MIN	37.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+45MIN	34.450 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+2HR	23.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+4HR	12.290 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+6HR	6.350 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+8HR	4.740 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER, EOI+24HR	0.822 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, PREDOSE	0.085 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+5MIN	40.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+2HR	17.950 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+4HR	9.765 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER, EOI+8HR	3.665 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+5MIN	48.150 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+2HR	29.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+4HR	15.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER, EOI+8HR	6.070 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER, PREDOSE	0.362 ng/mL

Secondary

Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 2, 3, 4, 5, 7, 10

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1 CROSSOVER	2.1460 Hours	Geometric Coefficient of Variation 66.2957
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2 CROSSOVER	4.7086 Hours	Geometric Coefficient of Variation 327.1693
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3 CROSSOVER	2.1828 Hours	Geometric Coefficient of Variation 54.257
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4 CROSSOVER	3.7809 Hours	Geometric Coefficient of Variation 121.5012
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5 CROSSOVER	1.4489 Hours	Geometric Coefficient of Variation 22.9248
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7 CROSSOVER	1.1078 Hours	Geometric Coefficient of Variation 38.4294
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10 CROSSOVER	1.9742 Hours	—

Secondary

Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Crossover Week 1, 4, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	8.6297 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	3336.2317 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	1016.7767 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7 CROSSOVER	23.2987 Hours	Geometric Coefficient of Variation 1163.1768
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10 CROSSOVER	2.2461 Hours	Geometric Coefficient of Variation 10.8792
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13 CROSSOVER	2.1918 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19 CROSSOVER	2.2090 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1 CROSSOVER	15.5839 Hours	Geometric Coefficient of Variation 156.6758
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4 CROSSOVER	8.2823 Hours	Geometric Coefficient of Variation 67.5066

Secondary

Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1 to 6, 9, 10, 12, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	1.7913 Hours	Geometric Coefficient of Variation 68.2418
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK19	1.3160 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	3.3936 Hours	Geometric Coefficient of Variation 231.5664
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	3.5628 Hours	Geometric Coefficient of Variation 254.2437
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	2.8077 Hours	Geometric Coefficient of Variation 90.0579
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	3.7449 Hours	Geometric Coefficient of Variation 206.4953
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	4.7658 Hours	Geometric Coefficient of Variation 328.9786
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	2.6641 Hours	Geometric Coefficient of Variation 106.891
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	0.8472 Hours	Geometric Coefficient of Variation 46.5385
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	0.7582 Hours	Geometric Coefficient of Variation 77.8995
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	4.2877 Hours	Geometric Coefficient of Variation 51.4222
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	9.5995 Hours	Geometric Coefficient of Variation 28.9474
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	19.3880 Hours	Geometric Coefficient of Variation 469.4324
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	2.6123 Hours	Geometric Coefficient of Variation 174.1372
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	3.2869 Hours	Geometric Coefficient of Variation 68.0644
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	1.1755 Hours	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	3.9070 Hours	Geometric Coefficient of Variation 210.2296
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	2.9851 Hours	Geometric Coefficient of Variation 142.5006
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	3.4171 Hours	Geometric Coefficient of Variation 154.747
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	3.3057 Hours	Geometric Coefficient of Variation 155.8241
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	3.6380 Hours	Geometric Coefficient of Variation 215.0417
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	2.8734 Hours	Geometric Coefficient of Variation 146.349
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	1.5753 Hours	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	0.8903 Hours	Geometric Coefficient of Variation 52.3388
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	2.0752 Hours	Geometric Coefficient of Variation 137.0553
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	1.9345 Hours	Geometric Coefficient of Variation 128.5751
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	1.1873 Hours	Geometric Coefficient of Variation 30.5239
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	2.1743 Hours	Geometric Coefficient of Variation 110.6625
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	1.6793 Hours	Geometric Coefficient of Variation 100.7945
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	1.8997 Hours	Geometric Coefficient of Variation 167.2107
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	1.3649 Hours	Geometric Coefficient of Variation 73.8778
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	1.9482 Hours	Geometric Coefficient of Variation 136.5929
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	5.8372 Hours	Geometric Coefficient of Variation 277.8089
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	3.1452 Hours	Geometric Coefficient of Variation 31.5377
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	3.0618 Hours	Geometric Coefficient of Variation 71.7607
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	5.4240 Hours	Geometric Coefficient of Variation 106.1862
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	1.9083 Hours	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	3.1800 Hours	Geometric Coefficient of Variation 29.9556
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	1.5023 Hours	Geometric Coefficient of Variation 73.2964
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	3.6785 Hours	Geometric Coefficient of Variation 30.4604

Secondary

Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1 to 6, 9, 10, 12, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	47.0402 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 73.0706
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK19	28.6164 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	39.0336 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 35.7876
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	18.8752 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 55.5837
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	19.8179 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 61.7906
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	46.2111 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 126.0831
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	69.7018 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 102.851
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	77.8444 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 108.544
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	46.6175 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 103.714
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	38.6047 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 101.8073
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	425.3023 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 189.71
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	338.2702 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 96.4149
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	285.9155 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 118.7575
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	173.6723 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 38.7832
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	63.1059 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 377.1988
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	79.7311 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	133.7003 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 132.4949
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	149.6756 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 122.4637
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	138.8428 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 132.3027
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	133.8118 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	145.6088 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 111.8033
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	130.5975 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 114.5345
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	150.3281 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 116.4078
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	84.7136 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 35.4645
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	245.7313 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 103.6711
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	304.3914 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 139.3329
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	272.8593 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 127.8989
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	246.7692 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 132.0408
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	318.5676 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 115.5291
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	276.5512 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 116.8407
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	297.4580 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 137.6797
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	199.9995 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 61.2526
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	198.6138 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 70.3728
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	203.4746 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 53.4979
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	216.6902 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 91.1146
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	255.0798 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	175.7315 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 63.3206
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	247.2823 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 79.1154
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	234.0111 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 85.9781
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	253.8358 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 103.5394

Secondary

Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1, 4, 7, 10, 13, 16, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK1	113.1657 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 7.851
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK4	87.6701 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 97.5597
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK7	108.6757 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 46.0604
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK13	24.5659 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK10	55.1481 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 20.7267
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK16	80.1101 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 3.0157
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK19	47.0437 HoursNanogram/ millilitre (hng/mL)	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK1	145.2959 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 49.6241
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK7	160.3952 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 60.7743
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK4	120.1116 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 37.5649
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK16	96.6895 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 103.2832
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK10	227.9506 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 144.4144
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)	WEEK13	262.4978 HoursNanogram/ millilitre (hng/mL)	Geometric Coefficient of Variation 16.2226

Secondary

Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1, 4, 7, 10, 13, 16, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK19	24.762 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK10	15.437 ng/mL	Geometric Coefficient of Variation 49.771
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK1	20.703 ng/mL	Geometric Coefficient of Variation 19.236
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK4	20.823 ng/mL	Geometric Coefficient of Variation 33.402
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK16	20.319 ng/mL	Geometric Coefficient of Variation 28.639
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK13	11.616 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK7	17.549 ng/mL	Geometric Coefficient of Variation 32.677
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK16	52.759 ng/mL	Geometric Coefficient of Variation 3.691
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK4	79.308 ng/mL	Geometric Coefficient of Variation 21.611
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK13	53.302 ng/mL	Geometric Coefficient of Variation 46.526
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK1	66.892 ng/mL	Geometric Coefficient of Variation 24.171
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK7	56.320 ng/mL	Geometric Coefficient of Variation 30.48
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)	WEEK10	67.238 ng/mL	Geometric Coefficient of Variation 38.878

Secondary

Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Pre-dose on weeks(W) 1-6,9,10,12,19,55;end of infusion(EOI)+5minute(min) on W 1-6, 9,10,12,19,55;EOI+4 hour(HR)/8 HR on W 1-6, 9, 10, 12, 19;EOI+15min/30min/45min/1HR on W 1-6, 9,12;EOI+24HR on W 1-6, 9,10,12; EOI+2HR on W 1-6,9,10,12,19,55

Population: Pharmacokinetic (PK) population included all participants from the All Treated Population for whom at least one PK sample was obtained and analyzed. The number analyzed for each timepoint reflects the number of participants from the Overall PK population with a non-missing value at the specified time point.

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+4HR	2.970 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+30MIN	14.750 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+2HR	6.210 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+5MIN	20.740 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+1HR	21.055 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+45MIN	13.150 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+8HR	0.473 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+15MIN	16.120 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+8HR	0.462 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+5MIN	18.575 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+24HR	0.054 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK55, EOI+2HR	5.510 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+5MIN	22.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+30MIN	16.800 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+1HR	12.510 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+45MIN	13.380 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK55, EOI+5MIN	13.500 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+5MIN	21.365 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+45MIN	14.090 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+2HR	6.990 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+4HR	1.850 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+24HR	0.268 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+1HR	11.400 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+15MIN	20.300 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+8HR	0.391 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+8HR	0.462 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+2HR	10.020 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+45MIN	23.095 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+5MIN	19.480 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+4HR	2.205 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+8HR	0.381 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+15MIN	17.260 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+15MIN	21.110 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+4HR	2.490 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+30MIN	15.290 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+2HR	7.880 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+2HR	7.370 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+5MIN	23.550 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+4HR	1.620 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+8HR	0.397 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+8HR	0.195 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+45MIN	12.550 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+30MIN	16.790 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+4HR	2.030 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+1HR	11.950 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+1HR	5.325 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+2HR	6.090 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+2HR	5.930 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+1HR	10.580 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+4HR	2.085 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+5MIN	17.250 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+45MIN	15.735 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK55, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+8HR	0.409 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+15MIN	18.880 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+4HR	1.540 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+8HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+2HR	5.280 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+15MIN	20.720 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+5MIN	19.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+2HR	3.205 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+4HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+4HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+1HR	14.545 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+2HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+1HR	7.700 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+24HR	0.067 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+45MIN	8.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+30MIN	11.570 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+45MIN	11.150 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+15MIN	17.340 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+5MIN	22.990 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+5MIN	24.245 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+30MIN	16.215 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+15MIN	27.620 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+30MIN	15.800 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+30MIN	25.495 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+8HR	17.930 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+8HR	3.470 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, PREDOSE	0.665 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+24HR	0.791 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+4HR	24.690 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+5MIN	27.850 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+5MIN	15.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+2HR	34.100 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+5MIN	9.390 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+1HR	21.300 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+2HR	8.460 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+2HR	11.500 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+5MIN	27.400 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+2HR	13.400 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+30MIN	17.050 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+4HR	6.190 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+2HR	14.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+4HR	7.400 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+2HR	24.100 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+8HR	2.840 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+4HR	18.800 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+24HR	3.460 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+4HR	8.605 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+5MIN	21.350 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+5MIN	21.350 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+8HR	5.480 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, EOI+5MIN	42.400 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+45MIN	14.365 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+5MIN	18.650 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK19, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+4HR	8.010 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+4HR	7.320 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+24HR	1.020 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+8HR	4.020 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+15MIN	18.590 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+2HR	14.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+4HR	5.072 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+24HR	0.516 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+2HR	12.700 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+24HR	0.856 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+8HR	0.746 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+15MIN	40.700 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+45MIN	31.420 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+2HR	16.200 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+5MIN	49.810 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+15MIN	45.700 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+30MIN	36.370 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+45MIN	31.750 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+1HR	31.230 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+5MIN	49.010 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+15MIN	44.120 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+30MIN	36.790 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+1HR	32.030 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+8HR	0.236 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+30MIN	33.500 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+45MIN	31.300 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+2HR	17.320 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+4HR	7.620 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+8HR	0.129 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+5MIN	47.173 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+15MIN	42.492 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+1HR	25.885 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+2HR	14.350 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+30MIN	32.860 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+45MIN	28.320 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+1HR	30.325 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+2HR	17.485 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+4HR	7.630 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+15MIN	46.830 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+4HR	3.020 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+5MIN	66.540 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+2HR	13.405 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+4HR	2.650 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+5MIN	44.700 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+30MIN	36.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+1HR	29.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+4HR	6.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+8HR	0.338 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+2HR	15.695 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+4HR	8.150 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+8HR	0.438 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+45MIN	34.510 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+2HR	17.600 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+4HR	8.480 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+5MIN	49.095 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+15MIN	41.540 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+1HR	28.030 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+30MIN	33.345 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+45MIN	27.900 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+4HR	5.495 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+5MIN	58.328 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+15MIN	37.845 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+8HR	1.642 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+24HR	0.201 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+5MIN	43.295 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+30MIN	38.160 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+45MIN	30.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+1HR	25.965 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+2HR	14.675 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, PREDOSE	3.150 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+5MIN	71.450 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+2HR	38.650 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+4HR	25.150 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK10, EOI+8HR	2.300 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+15MIN	47.080 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+30MIN	41.385 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+45MIN	29.580 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+1HR	24.850 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+8HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+5MIN	106.260 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+5MIN	101.655 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+15MIN	121.300 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+4HR	13.200 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+15MIN	106.120 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+1HR	63.890 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+5MIN	119.990 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+8HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+15MIN	99.440 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+30MIN	90.085 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+8HR	20.940 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+45MIN	85.550 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+15MIN	97.570 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+15MIN	132.160 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+4HR	10.710 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+5MIN	126.020 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+1HR	66.970 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+30MIN	92.780 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+45MIN	76.765 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+30MIN	108.240 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+4HR	17.490 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+5MIN	103.550 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+45MIN	85.520 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+30MIN	85.740 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+2HR	47.890 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+30MIN	111.920 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+1HR	75.860 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+2HR	31.510 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+1HR	73.750 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+4HR	19.080 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+45MIN	92.490 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+24HR	6.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+2HR	64.050 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+15MIN	99.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+1HR	72.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+2HR	41.550 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+5MIN	150.260 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+4HR	20.740 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+30MIN	92.590 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+15MIN	116.030 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+8HR	6.120 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+5MIN	113.140 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+2HR	36.110 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+30MIN	83.075 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+2HR	45.560 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+2HR	41.620 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+45MIN	70.485 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+1HR	62.310 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+1HR	76.440 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+2HR	32.970 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+8HR	8.370 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+45MIN	89.030 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+45MIN	87.250 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+4HR	11.380 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+30MIN	78.930 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+45MIN	79.810 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+8HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+4HR	14.945 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+1HR	69.760 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+8HR	2.845 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+4HR	23.080 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+15MIN	90.640 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, PREDOSE	5.130 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+5MIN	106.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+2HR	49.617 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+1HR	69.849 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+1HR	74.026 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+15MIN	94.482 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+30MIN	80.173 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+2HR	50.148 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+5MIN	112.617 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+4HR	20.212 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+5MIN	121.546 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+30MIN	85.103 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+15MIN	94.602 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+45MIN	69.923 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+24HR	0.686 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+2HR	32.906 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+8HR	2.564 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+4HR	14.279 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+5MIN	111.450 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+5MIN	112.175 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+4HR	13.288 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+15MIN	102.480 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+45MIN	68.947 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+45MIN	78.505 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+1HR	64.737 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+2HR	38.423 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+24HR	0.700 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+30MIN	76.850 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+5MIN	111.655 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+45MIN	70.156 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, EOI+30MIN	90.573 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+8HR	2.599 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+24HR	0.752 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+24HR	0.459 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+8HR	1.944 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+5MIN	102.851 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+1HR	56.589 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+4HR	3.917 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+30MIN	78.439 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+8HR	0.935 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, EOI+15MIN	104.424 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+24HR	0.269 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, PREDOSE	0.145 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK3, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+15MIN	86.184 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+5MIN	98.752 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+24HR	1.129 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+15MIN	96.102 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+30MIN	83.767 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+45MIN	80.187 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+8HR	7.987 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+1HR	70.788 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+2HR	38.384 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+4HR	28.923 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+1HR	61.492 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+5MIN	98.041 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+4HR	37.657 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+15MIN	90.104 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK12, EOI+30MIN	85.491 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+2HR	15.285 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+45MIN	66.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+1HR	40.026 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK9, EOI+2HR	48.390 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+1HR	59.051 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+2HR	39.142 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+45MIN	47.588 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK2, EOI+45MIN	75.977 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+4HR	12.886 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+30MIN	62.879 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK1, EOI+8HR	2.200 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK6, EOI+15MIN	86.413 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)	WEEK5, EOI+4HR	22.082 Nanogram/ millilitre (ng/mL)

Secondary

Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Pre-dose on W 1, 4, 7, 10, 13, 16, 19; EOI+5min/ 15min/ 30 min/ 45 min/1HR/ 2HR/ 4HR on W 1, 4, 7, 10, 13, 16, 19; EOI+8HR/ 24HR on W 1, 4, 7, 10, 13, 16

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+45MIN	6.717 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+8HR	1.306 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+24HR	0.224 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+5MIN	16.300 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+5MIN	11.616 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+1HR	6.132 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+2HR	3.484 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+8HR	0.380 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+24HR	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+5MIN	20.721 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+15MIN	18.115 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+30MIN	16.677 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+45MIN	14.784 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+1HR	12.920 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+2HR	9.099 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+4HR	5.529 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+8HR	1.455 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+24HR	0.284 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+5MIN	24.762 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+15MIN	20.382 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+30MIN	19.166 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+45MIN	15.938 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+1HR	13.778 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+2HR	7.581 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+4HR	4.616 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+5MIN	19.656 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+15MIN	17.848 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+30MIN	16.010 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+45MIN	14.122 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+1HR	12.503 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+2HR	8.103 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+24HR	0.213 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+5MIN	19.178 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+15MIN	19.738 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+30MIN	17.016 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+45MIN	15.065 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+1HR	14.628 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+2HR	9.483 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+4HR	3.133 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+8HR	1.067 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+24HR	0.172 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+5MIN	17.996 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+15MIN	15.603 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+30MIN	16.050 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+45MIN	14.383 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+1HR	13.182 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+2HR	8.885 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+4HR	4.126 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+8HR	1.730 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+15MIN	14.881 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+30MIN	14.029 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+45MIN	12.552 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+1HR	10.926 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+2HR	6.899 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+4HR	3.349 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+8HR	1.178 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+24HR	0.186 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+15MIN	9.839 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+30MIN	8.136 Nanogram/ millilitre (ng/mL)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+4HR	4.324 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+30MIN	52.583 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+15MIN	59.686 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+4HR	5.024 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+15MIN	51.354 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+8HR	0.867 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+24HR	0.162 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+30MIN	48.956 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+30MIN	45.104 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+24HR	0.249 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+45MIN	41.514 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+30MIN	43.613 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+5MIN	72.010 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+1HR	32.591 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+45MIN	53.366 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+5MIN	52.322 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+45MIN	42.186 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+2HR	14.133 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+1HR	39.095 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+45MIN	34.381 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+2HR	25.151 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+4HR	15.093 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+24HR	0.390 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+8HR	5.522 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+8HR	2.970 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+24HR	1.165 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+1HR	30.738 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+5MIN	52.777 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+5MIN	79.138 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+15MIN	37.137 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+1HR	44.280 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+30MIN	25.695 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+15MIN	60.396 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+45MIN	25.281 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+2HR	17.308 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+1HR	18.798 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+30MIN	42.864 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+2HR	13.221 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK13, EOI+15MIN	54.481 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+4HR	5.104 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+45MIN	36.750 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+8HR	1.806 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+4HR	4.005 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK16, EOI+24HR	0.297 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+1HR	31.770 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+2HR	29.161 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+5MIN	48.719 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+2HR	14.780 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+15MIN	41.813 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+8HR	0.978 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+30MIN	33.774 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+4HR	2.769 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+45MIN	28.790 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+24HR	0.667 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+1HR	22.454 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK4, EOI+8HR	0.712 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+2HR	21.388 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+15MIN	59.605 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK19, EOI+4HR	10.894 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK10, EOI+4HR	14.945 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, PREDOSE	0.000 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK7, EOI+5MIN	56.701 Nanogram/ millilitre (ng/mL)
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)	WEEK1, EOI+5MIN	68.092 Nanogram/ millilitre (ng/mL)

Secondary

Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1 to 6, 9, 10, 12, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK19	15.700 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	20.791 ng/mL	Geometric Coefficient of Variation 57.142
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	17.284 ng/mL	Geometric Coefficient of Variation 38.137
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	21.648 ng/mL	Geometric Coefficient of Variation 44.92
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	24.710 ng/mL	Geometric Coefficient of Variation 33.028
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	25.079 ng/mL	Geometric Coefficient of Variation 47.896
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	18.057 ng/mL	Geometric Coefficient of Variation 42.913
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	19.956 ng/mL	Geometric Coefficient of Variation 44.055
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	18.972 ng/mL	Geometric Coefficient of Variation 61.73
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	24.213 ng/mL	Geometric Coefficient of Variation 8.391
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	20.669 ng/mL	Geometric Coefficient of Variation 37.429
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	39.421 ng/mL	Geometric Coefficient of Variation 40.108
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	6.152 ng/mL	Geometric Coefficient of Variation 248.49
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	19.922 ng/mL	Geometric Coefficient of Variation 59.477
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	27.442 ng/mL	Geometric Coefficient of Variation 24.724
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	47.747 ng/mL	Geometric Coefficient of Variation 66.571
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	53.434 ng/mL	Geometric Coefficient of Variation 38.959
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	46.712 ng/mL	Geometric Coefficient of Variation 50.725
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	49.458 ng/mL	Geometric Coefficient of Variation 38.252
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	51.851 ng/mL	Geometric Coefficient of Variation 84.399
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	128.974 ng/mL	Geometric Coefficient of Variation 71.075
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	50.470 ng/mL	Geometric Coefficient of Variation 34.755
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	43.320 ng/mL	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK10	72.100 ng/mL	—
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	120.172 ng/mL	Geometric Coefficient of Variation 25.81
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	115.067 ng/mL	Geometric Coefficient of Variation 21.459
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	114.148 ng/mL	Geometric Coefficient of Variation 27.392
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	112.085 ng/mL	Geometric Coefficient of Variation 26.349
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	118.978 ng/mL	Geometric Coefficient of Variation 21.611
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	151.763 ng/mL	Geometric Coefficient of Variation 34.837
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	119.378 ng/mL	Geometric Coefficient of Variation 46.814
Part 1A: GSK3745417 0.4 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	116.290 ng/mL	Geometric Coefficient of Variation 35.137
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK1	115.244 ng/mL	Geometric Coefficient of Variation 24.732
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK4	125.171 ng/mL	Geometric Coefficient of Variation 30.301
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK2	111.111 ng/mL	Geometric Coefficient of Variation 31.847
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK12	116.269 ng/mL	—
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK5	117.339 ng/mL	Geometric Coefficient of Variation 20.709
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK9	111.267 ng/mL	Geometric Coefficient of Variation 25.162
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK6	111.399 ng/mL	Geometric Coefficient of Variation 13.175
Part 1A: GSK3745417 0.2 mg (Q1W)	Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)	WEEK3	103.552 ng/mL	Geometric Coefficient of Variation 24.989

Secondary

Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 alone.

Time frame: Week 1, 4, 7, 10, 13, 16, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK10	3.8978 Hours	Geometric Coefficient of Variation 37.0772
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK4	3.0907 Hours	Geometric Coefficient of Variation 64.7708
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK13	1.6765 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK16	3.5409 Hours	Geometric Coefficient of Variation 35.5513
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK19	1.4041 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK7	4.3622 Hours	Geometric Coefficient of Variation 8.6103
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK1	3.3703 Hours	Geometric Coefficient of Variation 8.6696
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK1	3.3373 Hours	Geometric Coefficient of Variation 26.781
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK16	2.3492 Hours	Geometric Coefficient of Variation 146.8761
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK10	4.0823 Hours	Geometric Coefficient of Variation 26.7208
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK7	7.5933 Hours	Geometric Coefficient of Variation 703.4471
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK13	4.7440 Hours	Geometric Coefficient of Variation 42.2168
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)	WEEK4	3.2810 Hours	Geometric Coefficient of Variation 97.7614

Secondary

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 2, 5, 6, 8

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	48.4490 h*ng/mL	Geometric Coefficient of Variation 7.7001
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	35.1903 h*ng/mL	Geometric Coefficient of Variation 67.655
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	44.6483 h*ng/mL	Geometric Coefficient of Variation 53.3204
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1	61.7410 h*ng/mL	Geometric Coefficient of Variation 41.638
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	50.7155 h*ng/mL	Geometric Coefficient of Variation 51.4681
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	187.0690 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	561.8580 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	262.5058 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	163.2896 h*ng/mL	—

Secondary

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1 to 5, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	216.7790 h*ng/mL	Geometric Coefficient of Variation 129.0498
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	271.1541 h*ng/mL	Geometric Coefficient of Variation 167.9069
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	105.7925 h*ng/mL	Geometric Coefficient of Variation 37.9802
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	69.6510 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	326.3424 h*ng/mL	Geometric Coefficient of Variation 105.6259
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	87.5461 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	43.3152 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	93.7275 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	171.3085 h*ng/mL	Geometric Coefficient of Variation 31.4407
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19	476.8171 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	128.9958 h*ng/mL	Geometric Coefficient of Variation 39.4126
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	216.5303 h*ng/mL	Geometric Coefficient of Variation 118.842
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	471.1217 h*ng/mL	Geometric Coefficient of Variation 96.1181
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	310.4697 h*ng/mL	Geometric Coefficient of Variation 81.1473
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	130.8498 h*ng/mL	Geometric Coefficient of Variation 76.6372
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	130.9849 h*ng/mL	Geometric Coefficient of Variation 80.5132
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	122.3525 h*ng/mL	Geometric Coefficient of Variation 31.6306

Secondary

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 4, 7, 10, 13, 19, 91

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91	31.1811 h*ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	41.2241 h*ng/mL	Geometric Coefficient of Variation 46.826
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	42.0297 h*ng/mL	Geometric Coefficient of Variation 92.4823
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	44.0290 h*ng/mL	Geometric Coefficient of Variation 208.4637
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	103.5186 h*ng/mL	Geometric Coefficient of Variation 400.0481
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13	189.3316 h*ng/mL	Geometric Coefficient of Variation 16.9323
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	217.9598 h*ng/mL	Geometric Coefficient of Variation 148.0574
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19	539.0039 h*ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	136.9391 h*ng/mL	Geometric Coefficient of Variation 91.3047
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	283.2979 h*ng/mL	Geometric Coefficient of Variation 364.42
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	110.3856 h*ng/mL	Geometric Coefficient of Variation 83.9274

Secondary

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 2, 5, 6, 8

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	15.326 ng/mL	Geometric Coefficient of Variation 18.09
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	12.552 ng/mL	Geometric Coefficient of Variation 29.984
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	18.860 ng/mL	Geometric Coefficient of Variation 10.751
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1	19.695 ng/mL	Geometric Coefficient of Variation 2.817
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	12.429 ng/mL	Geometric Coefficient of Variation 39.182
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	64.400 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	18.700 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	82.500 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	53.000 ng/mL	—

Secondary

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1 to 5, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	16.300 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	25.829 ng/mL	Geometric Coefficient of Variation 11.287
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	17.709 ng/mL	Geometric Coefficient of Variation 44.248
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	20.725 ng/mL	Geometric Coefficient of Variation 16.041
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	29.271 ng/mL	Geometric Coefficient of Variation 35.456
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	19.600 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	38.000 ng/mL	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	22.100 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	51.623 ng/mL	Geometric Coefficient of Variation 17.632
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	41.366 ng/mL	Geometric Coefficient of Variation 31.911
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	49.347 ng/mL	Geometric Coefficient of Variation 27.385
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	42.791 ng/mL	Geometric Coefficient of Variation 19.418
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	51.212 ng/mL	Geometric Coefficient of Variation 31.808
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19	42.900 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	40.056 ng/mL	Geometric Coefficient of Variation 72.883
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	50.660 ng/mL	Geometric Coefficient of Variation 10.597
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	44.277 ng/mL	Geometric Coefficient of Variation 29.284

Secondary

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 4, 7, 10, 13, 19, 91

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	23.184 ng/mL	Geometric Coefficient of Variation 13.852
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	24.297 ng/mL	Geometric Coefficient of Variation 5.545
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	23.179 ng/mL	Geometric Coefficient of Variation 29.068
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	25.904 ng/mL	Geometric Coefficient of Variation 25.29
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91	19.900 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	38.655 ng/mL	Geometric Coefficient of Variation 20.087
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19	112.000 ng/mL	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	42.961 ng/mL	Geometric Coefficient of Variation 26.296
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	29.947 ng/mL	Geometric Coefficient of Variation 33.758
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	42.936 ng/mL	Geometric Coefficient of Variation 20.005
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13	50.528 ng/mL	Geometric Coefficient of Variation 25.89

Secondary

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Pre-dose and EOI+5min/ 2HR/ 4HR on W 1, 2, 5, 6, 8, 11, 14, 20, 38; EOI+15min/ 30min/ 45min/ 1HR/ 6HR on W 1 and 8; EOI+8HR in W 1, 2, 5, 6, 8; EOI+24HR on W 1, 2, 5, 8.

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+8HR	0.374 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+4HR	2.140 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+8HR	0.425 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+5MIN	14.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+2HR	6.910 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+24HR	0.144 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+2HR	7.790 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+4HR	3.430 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+8HR	1.500 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+15MIN	17.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+30MIN	14.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+45MIN	11.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+1HR	10.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+2HR	6.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+4HR	1.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+6HR	1.040 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+8HR	0.626 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+5MIN	15.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+2HR	8.790 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+4HR	4.910 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+5MIN	10.990 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+2HR	7.010 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+4HR	2.515 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK20, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK20, EOI+5MIN	19.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK20, EOI+2HR	11.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK20, EOI+4HR	6.390 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK38, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK38, EOI+5MIN	19.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK38, EOI+2HR	6.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK38, EOI+4HR	2.030 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+5MIN	12.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+4HR	3.750 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+8HR	1.440 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+5MIN	17.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+5MIN	18.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+5MIN	19.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+15MIN	19.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+30MIN	15.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+45MIN	13.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+1HR	11.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+2HR	8.360 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+4HR	2.290 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+6HR	0.838 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, EOI+24HR	0.204 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+2HR	5.930 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, PREDOSE	0.464 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+24HR	0.571 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+2HR	28.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+2HR	29.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+4HR	15.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+6HR	7.130 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+2HR	27.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+5MIN	53.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+5MIN	56.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+4HR	13.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+8HR	5.170 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6, EOI+8HR	5.670 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+4HR	14.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+5MIN	64.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+24HR	0.548 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+15MIN	52.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+4HR	6.850 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+30MIN	50.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+5MIN	18.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+45MIN	43.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+2HR	17.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+1HR	40.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+8HR	16.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK11, EOI+5MIN	68.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2, EOI+24HR	9.210 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+2HR	26.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+5MIN	82.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK14, EOI+2HR	12.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5, EOI+8HR	5.740 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8, EOI+4HR	11.900 ng/mL

Secondary

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Pre-dose,EOI+5min/2HR/4HR on W 1 to 5, 7, 10, 13, 19, 37, 55; EOI+15min/ 30min/ 45 min/ 1HR on W 1, 4, 7; EOI+8HR on W 1 to 5, 7, 10, 13, 19; EOI+24HR on W 1 to 5, 7, 10

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+2HR	14.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+4HR	10.105 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+2HR	17.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+2HR	18.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+4HR	12.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+5MIN	22.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+8HR	6.470 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+5MIN	22.550 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+2HR	9.220 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+4HR	8.610 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+4HR	5.110 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+45MIN	21.150 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+15MIN	23.150 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+1HR	23.850 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+8HR	5.105 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+8HR	4.275 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+30MIN	20.450 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+24HR	0.675 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+8HR	1.140 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+45MIN	17.550 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+5MIN	16.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+5MIN	27.950 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+2HR	10.375 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+1HR	18.050 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+4HR	5.670 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+2HR	6.990 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+8HR	2.484 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+2HR	12.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+4HR	7.735 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+5MIN	19.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+15MIN	19.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+4HR	3.090 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+30MIN	15.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+8HR	2.580 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+45MIN	12.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+15MIN	24.950 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+1HR	10.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+24HR	0.390 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+8HR	0.463 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+5MIN	38.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+5MIN	26.350 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+2HR	9.940 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+5MIN	19.250 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+4HR	4.570 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+30MIN	25.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+8HR	0.782 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+24HR	0.677 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+5MIN	45.250 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+2HR	19.050 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+4HR	8.720 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+8HR	3.130 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5, EOI+24HR	0.719 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+15MIN	40.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+30MIN	36.750 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+45MIN	32.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+1HR	29.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+24HR	0.528 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+5MIN	49.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+2HR	17.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+4HR	6.710 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+8HR	4.840 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+4HR	15.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+8HR	9.830 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+24HR	3.915 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+5MIN	49.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+5MIN	39.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+15MIN	35.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+2HR	19.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+4HR	10.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+5MIN	45.950 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+2HR	18.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+4HR	8.515 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7, EOI+8HR	2.340 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10, EOI+24HR	0.250 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+5MIN	49.950 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+2HR	22.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+4HR	10.120 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK55, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK55, EOI+5MIN	123.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK55, EOI+2HR	10.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13, EOI+8HR	4.825 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19, EOI+5MIN	44.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19, EOI+2HR	17.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19, EOI+4HR	6.090 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19, EOI+8HR	21.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK37, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK37, EOI+5MIN	51.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK37, EOI+2HR	16.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK37, EOI+4HR	6.150 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK55, EOI+4HR	3.310 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+5MIN	54.750 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+15MIN	50.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+30MIN	43.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+45MIN	39.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+1HR	34.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+2HR	25.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+4HR	14.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+8HR	5.880 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1, EOI+24HR	1.007 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+5MIN	50.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2, EOI+2HR	25.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+2HR	25.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+4HR	14.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+8HR	6.535 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3, EOI+24HR	2.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+30MIN	31.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+45MIN	27.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+1HR	25.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4, EOI+8HR	3.125 ng/mL

Secondary

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Pre-dose on W 1, 4, 7, 10, 13, 19, 37, 55, 73, 91; EOI+5min/ 4HR on W 1, 4, 7, 10, 13, 19, 37, 55, 91; EOI+15min/ 30min/ 45min/ 1HR/ 6HR on W 1, 4, 7; EOI+2HR on W 1, 4, 7, 10, 13, 19, 37, 55, 73; EOI+8HR/24 HR on W 1, 4, 7, 10, 13, 19, 91

Arm	Measure	Group	Value (MEDIAN)
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+5MIN	19.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, EOI+5MIN	22.700 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+5MIN	24.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, EOI+2HR	2.050 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+15MIN	20.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+4HR	0.870 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+30MIN	16.050 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, EOI+4HR	0.338 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+45MIN	12.800 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+4HR	5.870 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+1HR	10.370 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK73, PREDOSE	0.204 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+2HR	3.905 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK73, EOI+2HR	2.770 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+4HR	1.064 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+6HR	0.355 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91, EOI+5MIN	19.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+8HR	0.198 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91, EOI+4HR	1.070 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91, EOI+8HR	0.242 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+5MIN	21.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+15MIN	18.300 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+30MIN	14.500 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+5MIN	23.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+45MIN	11.400 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+2HR	2.860 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+1HR	9.080 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+15MIN	20.550 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+2HR	4.130 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+4HR	0.847 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+30MIN	16.600 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+6HR	0.225 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+5MIN	20.350 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+8HR	0.137 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+45MIN	13.100 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+24HR	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, EOI+5MIN	27.200 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+1HR	10.355 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+5MIN	22.900 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, EOI+2HR	3.280 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+2HR	4.270 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+2HR	4.260 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+4HR	1.080 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+8HR	0.399 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+8HR	0.094 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+4HR	1.298 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, EOI+4HR	0.605 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+6HR	0.512 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+2HR	4.205 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+8HR	0.245 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, PREDOSE	0.000 ng/mL
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+24HR	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+8HR	2.040 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+5MIN	51.350 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+2HR	25.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+4HR	12.190 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+8HR	4.060 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, EOI+24HR	1.227 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+5MIN	85.950 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+2HR	43.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+4HR	23.600 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+8HR	17.500 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19, EOI+24HR	3.490 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, EOI+2HR	20.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK37, EOI+4HR	7.430 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, EOI+2HR	17.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK55, EOI+4HR	8.660 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+5MIN	43.250 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+15MIN	39.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+30MIN	34.050 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+45MIN	29.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+1HR	26.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+2HR	16.050 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+4HR	6.055 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+6HR	2.745 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+8HR	1.160 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1, EOI+24HR	0.302 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+5MIN	42.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+15MIN	40.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+30MIN	34.700 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+45MIN	31.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+1HR	28.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+2HR	16.650 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+4HR	6.095 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+6HR	2.360 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+8HR	1.141 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4, EOI+24HR	0.221 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+5MIN	39.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+15MIN	34.300 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+30MIN	28.100 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+45MIN	26.400 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+1HR	22.900 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+2HR	16.250 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+4HR	6.820 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+6HR	3.610 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7, EOI+24HR	0.482 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, PREDOSE	0.000 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+5MIN	28.800 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+2HR	15.550 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+4HR	7.200 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+8HR	3.135 ng/mL
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10, EOI+24HR	1.015 ng/mL

Secondary

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 2, 5, 6, 8

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	2.2228 Hours	Geometric Coefficient of Variation 0.3535
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	2.9851 Hours	Geometric Coefficient of Variation 75.7387
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	2.1554 Hours	Geometric Coefficient of Variation 97.416
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK1	2.8013 Hours	Geometric Coefficient of Variation 71.6405
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	2.1751 Hours	Geometric Coefficient of Variation 65.5517
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK8	4.4423 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK2	22.0749 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK5	4.4441 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)	WEEK6	2.1489 Hours	—

Secondary

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1 to 5, 7, 10, 13, 19

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	3.8954 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	4.9496 Hours	Geometric Coefficient of Variation 25.3441
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	5.4788 Hours	Geometric Coefficient of Variation 163.2744
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	8.0669 Hours	Geometric Coefficient of Variation 323.3053
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	9.9205 Hours	Geometric Coefficient of Variation 148.2505
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	1.7032 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	1.8660 Hours	—
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	2.2804 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK10	2.5380 Hours	Geometric Coefficient of Variation 40.5521
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK4	3.7841 Hours	Geometric Coefficient of Variation 83.5863
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK5	2.5329 Hours	Geometric Coefficient of Variation 39.3756
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK19	6.7964 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK1	6.6082 Hours	Geometric Coefficient of Variation 97.7169
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK7	5.5454 Hours	Geometric Coefficient of Variation 43.6477
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK2	3.2754 Hours	Geometric Coefficient of Variation 147.9302
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK13	2.3912 Hours	Geometric Coefficient of Variation 21.7772
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)	WEEK3	2.3642 Hours	Geometric Coefficient of Variation 72.3718

Secondary

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3745417 in combination with dostarlimab.

Time frame: Week 1, 4, 7, 10, 13, 19, 91

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	1.6491 Hours	Geometric Coefficient of Variation 105.7556
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	1.7825 Hours	Geometric Coefficient of Variation 64.9647
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	1.7101 Hours	Geometric Coefficient of Variation 121.4103
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	1.1499 Hours	Geometric Coefficient of Variation 54.3836
Part 1A: GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK91	1.2513 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK7	10.1871 Hours	Geometric Coefficient of Variation 122.2331
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK19	6.5557 Hours	—
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK1	4.5289 Hours	Geometric Coefficient of Variation 65.1077
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK10	3.9067 Hours	Geometric Coefficient of Variation 59.4336
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK4	5.4869 Hours	Geometric Coefficient of Variation 96.3549
Part 1A: Japan GSK3745417 0.1 mg (Q1W)	Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)	WEEK13	5.6356 Hours	Geometric Coefficient of Variation 1.5314

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Masking description

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Contacts

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Crossover Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)

Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)

Parts 1A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Parts 2A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Parts 2A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) by Severity

Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Crossover Phase: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Crossover Phase: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Crossover Phase: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Crossover Phase: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Part 1A: Apparent Terminal Phase Half-life (t1/2) Following Administration of GSK3745417 Alone (Q1W)

Part 1A: Area Under the Concentration-time Curve (AUC0-tau) Following Administration of GSK3745417 Alone (Q1W)

Part 1A: AUC(0-tau) Following Administration of GSK3745417 Alone (Q3W)

Part 1A: Cmax Following Administration of GSK3745417 Alone (Q3W)

Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q1W)

Part 1A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 Alone (Q3W)

Part 1A: Maximum Observed Concentration (Cmax) Following Administration of GSK3745417 Alone (Q1W)

Part 1A: T1/2 Following Administration of GSK3745417 Alone (Q3W)

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Part 2A: AUC(0-tau) Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Part 2A: Cmax Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Part 2A: GSK3745417 Concentrations in Plasma Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Imaging Q1W)

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)

Part 2A: T1/2 Following Administration of GSK3745417 in Combination With Dostarlimab (Q3W)